Caris Life Sciences, Inc. Common Stock (CAI) - Total Liabilities
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has total liabilities worth $568.90 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Caris Life Sciences, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
Caris Life Sciences, Inc. Common Stock - Total Liabilities Trend (2003–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Caris Life Sciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Frontdoor Inc
NASDAQ:FTDR
|
USA | $1.94 Billion |
|
Alaska Air Group Inc
NYSE:ALK
|
USA | $16.57 Billion |
|
Faw Car Co Ltd
SHE:000800
|
China | CN¥55.95 Billion |
|
Seaboard Corporation
NYSE MKT:SEB
|
USA | $3.07 Billion |
|
SentinelOne Inc
NYSE:S
|
USA | $1.00 Billion |
|
Acter Co Ltd
TWO:5536
|
Taiwan | NT$21.90 Billion |
|
Duolingo Inc
NASDAQ:DUOL
|
USA | $666.23 Million |
|
CommScope Holding Co Inc
NASDAQ:COMM
|
USA | $9.01 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Caris Life Sciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CAI market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caris Life Sciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caris Life Sciences, Inc. Common Stock (2003–2025)
The table below shows the annual total liabilities of Caris Life Sciences, Inc. Common Stock from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $548.36 Million | -80.71% |
| 2024-12-31 | $2.84 Billion | +11.13% |
| 2023-12-31 | $2.56 Billion | +5.72% |
| 2022-12-31 | $2.42 Billion | +26.65% |
| 2020-12-31 | $1.91 Billion | -13.50% |
| 2019-12-31 | $2.21 Billion | -4.45% |
| 2018-12-31 | $2.31 Billion | +23.84% |
| 2017-12-31 | $1.87 Billion | +16.77% |
| 2016-12-31 | $1.60 Billion | +4.80% |
| 2015-12-31 | $1.53 Billion | +12.74% |
| 2014-12-31 | $1.35 Billion | +7.34% |
| 2013-12-31 | $1.26 Billion | +21.07% |
| 2012-12-31 | $1.04 Billion | +47.75% |
| 2011-12-31 | $704.63 Million | +69.47% |
| 2010-12-31 | $415.78 Million | +69.72% |
| 2009-12-31 | $244.99 Million | -18.02% |
| 2008-12-31 | $298.84 Million | +31.10% |
| 2007-12-31 | $227.95 Million | -10.69% |
| 2006-12-31 | $255.25 Million | +72.85% |
| 2005-12-31 | $147.67 Million | -6.62% |
| 2004-12-31 | $158.14 Million | -11.12% |
| 2003-12-31 | $177.92 Million | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more